InnoCare Pharma Ltd. (HK:9969) has released an update.
InnoCare Pharma Ltd. has announced a significant advancement in developing treatments for multiple sclerosis, having concluded End of Phase 2 discussions with the U.S. FDA and agreed to initiate Phase 3 studies for their drug orelabrutinib. The company is set to begin trials in patients with Primary Progressive and Secondary Progressive Multiple Sclerosis, marking a step forward in addressing unmet medical needs in this area. They caution, however, that the development, marketing, and commercialization of orelabrutinib is still not guaranteed.
For further insights into HK:9969 stock, check out TipRanks’ Stock Analysis page.
